GlaxoSmithKline plc (LON:GSK) has received an average rating of “Hold” from the twenty-two analysts that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 1,689.48 ($22.21).

A number of analysts recently issued reports on the stock. Jefferies Group LLC lifted their price target on shares of GlaxoSmithKline plc from GBX 1,800 ($23.67) to GBX 1,900 ($24.98) and gave the stock a “buy” rating in a research note on Friday, June 16th. Liberum Capital restated a “buy” rating and issued a GBX 1,900 ($24.98) price target on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. Deutsche Bank AG restated a “hold” rating and issued a GBX 1,720 ($22.61) price target on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,750 ($23.01) price target on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. Finally, Barclays PLC restated an “equal weight” rating and issued a GBX 1,550 ($20.38) price target on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd.

In related news, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.27) per share, for a total transaction of £13,930.98 ($18,315.78). Also, insider Manvinder Singh Banga acquired 2,267 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($21.02) per share, for a total transaction of £36,249.33 ($47,658.86). Over the last 90 days, insiders have purchased 3,153 shares of company stock worth $5,055,853.

GlaxoSmithKline plc (GSK) opened at 1522.00 on Thursday. The stock has a 50 day moving average of GBX 1,500.18 and a 200 day moving average of GBX 1,586.54. The firm’s market cap is GBX 74.40 billion. GlaxoSmithKline plc has a one year low of GBX 1,444.00 and a one year high of GBX 1,724.50.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Given Consensus Recommendation of “Hold” by Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/12/glaxosmithkline-plc-gsk-given-consensus-recommendation-of-hold-by-analysts.html.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.